Pharmaceuticals News

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that...

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will...

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies...

Cannara appoints Nicholas Fozard as Chief Financial Officer as Niko Sosiak transitions fully into his role as Chief Operating Officer.

MONTRÉAL, 01 sept. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous ») (TSX: LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement intégré de cannabis...

Scribe Therapeutics to participate in upcoming investor conferences

MIRA reports positive 7-day toxicology results for non-opioid MIRA-55, supporting continued IND-enabling development for inflammatory pain.

In post hoc analysis of CARES-310 trial, combination improved mPFS versus sorafenib across age subgroupsCombination also improved mOS versus sorafenib in patients <50 years and ≥50 yearsElevar is...

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug...

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary...